HRTX - Heron's HTX-011 long term data published in a medical journal

Heron Therapeutics ([[HRTX]] +0.1%) has announced that the results from an EPOCH 1 follow-on study evaluating HTX-011 in bunionectomy (surgery that corrects a deformed area of the foot near the big toe), have been published online, by the Journal of the American Podiatric Medical Association.In this study, 77% of patients receiving HTX-011, along with postoperative over-the-counter oral acetaminophen and ibuprofen, remained opioid-free through the 72-hour period following surgery and continued to be opioid-free through 28 days of recovery. 71% of the patients receiving HTX-011 did not experience severe pain.HTX-011 is a dual-acting, fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam.HTX-011 was well tolerated and demonstrated no safety concerns when used with postoperative non-opioid MMAs (OTC acetaminophen and ibuprofen).The company refiled marketing application with the FDA seeking approval for HTX-011 for management of postoperative pain, in November last year.

For further details see:

Heron's HTX-011 long term data published in a medical journal